Boehringer Ingelheim announces finalists of the Making More Health Accelerator Program

Boehringer IngelheimBoehringer Ingelheim, one of the world's leading pharmaceutical companies, recently announced to support two projects of its Making More Health Accelerator Program: Melissa Menke, CEO of Access Ayfa and Joost van Engen, CEO of Healthy Entrepreneurs.

Four social ventures participated in the 2018 - 2019 accelerator program, where they developed innovative business models to solve unmet medical needs in sub Saharan Africa. Boehringer Ingelheim will continue to support the scale up of two of these models through funding of €150,000 per social venture. By using this unique approach, Boehringer Ingelheim is creating a win for communities by developing innovative and sustainable care delivery models, thus improving access to healthcare.

Melissa Menke pitched for a comprehensive diabetes and hypertension screening and clinical management program within low-income populations. Her organization, Access Afya, is a primary healthcare enterprise providing quality healthcare to low income groups in slums in Nairobi, Melissa aims to have 50 clinics across Kenya by 2021. Joost Van Engen, the founder of Healthy Entrepreneurs, pitched on a last mile distribution model for medicines and other basic commodities in rural western Kenya through a network of community entrepreneurs. With this concept, Healthy Entrepreneurs will be able to offer screening services, disease awareness and provide, through a combination of telemedicine and in-person doctor visits, accessible and affordable healthcare services.

"The patients will be the most important part of this program. Many people do not have the right access to quality treatment in Africa. By supporting the social entrepreneurs, patients will be provided with better access to healthcare." Ayman Eissa, Head of Human Pharma, Boehringer Ingelheim META.

The Making More Health (MMH) Accelerator is an 11-month business accelerator program, designed through a collaboration between Boehringer Ingelheim and Ashoka. Boehringer's business insights combined with Ashoka's extensive knowledge on social entrepreneurship gives a perfect foundation to provide a structured process to engage with social entrepreneurs and co-create successful business models.

Boehringer Ingelheim's initiative "Making More Health" aims to establish a network of social enterprises in Kenya, Nigeria and Ghana by building an ecosystem ‘on the ground’ which will help in developing holistic models that will sustainably provide quality healthcare to underserved communities.

About Boehringer Ingelheim

Improving the health of humans and animals is the goal of the research-driven pharmaceutical company Boehringer Ingelheim. The focus in doing so is on diseases for which no satisfactory treatment option exists to date. The company therefore concentrates on developing innovative therapies that can extend patients’ lives. In animal health, Boehringer Ingelheim stands for advanced prevention.

Family-owned since it was established in 1885, Boehringer Ingelheim is one of the pharmaceutical industry’s top 20 companies. Some 50,000 employees create value through innovation daily for the three business areas human pharmaceuticals, animal health and biopharmaceuticals. In 2018, Boehringer Ingelheim achieved net sales of around 17.5 billion euros. R&D expenditure of almost 3.2 billion euros, corresponded to 18.1 per cent of net sales.

As a family-owned company, Boehringer Ingelheim plans in generations and focuses on long-term success. The company therefore aims at organic growth from its own resources with simultaneous openness to partnerships and strategic alliances in research. In everything it does, Boehringer Ingelheim naturally adopts responsibility towards mankind and the environment.

Most Popular Now

Regorafenib to be tested in brain cancer patients …

Bayer announced that the regorafenib arm of the platform trial "GBM AGILE" (Glioblastoma Adaptive Global Innovative Learning Environment) opened for enrollment in the US ...

Sanofi and Google to develop new healthcare Innova…

Sanofi and Google will establish a new virtual Innovation Lab with the ambition to radically transform how future medicines and health services are delivered by tapping i...

Bristol-Myers Squibb provides update on pending me…

Bristol-Myers Squibb Company (NYSE: BMY) today provided an update on the approval process and timeline for the Company’s pending merger with Celgene Corporation (NASDAQ: ...

Artificial DNA can control release of active ingre…

A drug with three active ingredients that are released in sequence at specific times: Thanks to the work of a team at the Technical University of Munich (TUM), what was o...

LEO Pharma completes the acquisition of Bayer’s pr…

LEO Pharma and Bayer announced today the achievement of the relevant closing conditions to allow the transfer of Bayer’s global prescription dermatology business to LEO P...

Pathogen engineered to self-destruct underlies can…

A team of investigators has developed a cancer vaccine technology using live, attenuated pathogens as vectors. A feature of the vaccine causes these bacteria to self-dest...

Novartis successfully completes acquisition of Xii…

Novartis today announced that it has completed its acquisition of Xiidra® (lifitegrast ophthalmic solution) 5%, the first and only prescription treatment approved to trea...

How gastric stem cells fight bacteria

Stem cells are not only key players in tissue regeneration, they are also capable of taking direct action against bacteria. This is the finding of a study conducted by re...

New study showing drug prolongs life for patients …

Women with ovarian cancer who have undergone four or more rounds of chemotherapy typically haven't had much hope that another treatment option will lengthen their lives i...

Pfizer completes acquisition of Therachon

Pfizer Inc. (NYSE: PFE) announced the successful completion of its acquisition of the privately held clinical-stage biotechnology company Therachon Holding AG. Under the ...

Sports playbook helps doctors predict cancer patie…

In this season of global soccer competitions and hotly contested political primaries, bookies and pundits are scouring every evolving scrap of information and sifting thr...

FDA seeks public feedback on new drug approval tra…

Today the U.S. Food and Drug Administration issued a Federal Register notice, New Drugs Regulatory Program Modernization: Improving Approval Package Documentation, to ope...